Hardcastle Sarah J, Leyton-Román Marta, Maxwell-Smith Chloe, Hince Dana
Sport and Physical Activity Research Centre, Sheffield Hallam University, Sheffield, United Kingdom.
Institute for Health Research, The University of Notre Dame, Fremantle, WA, Australia.
Front Oncol. 2024 Sep 6;14:1368119. doi: 10.3389/fonc.2024.1368119. eCollection 2024.
The PPARCS trial examined the efficacy of a distance-based wearable and health coaching intervention to increase physical activity (PA) in breast and colorectal cancer (CRC) survivors living in non-metropolitan areas. This paper examines the effects of the intervention on health-related quality of life (HRQoL) at 12 weeks (T2; end of intervention) and 24 weeks (T3; follow-up).
Participants that were insufficiently physically active and had successfully completed cancer treatment were randomised to an intervention or control group. PA was assessed using an ActiGraph (GT9X) at baseline, T2, and T3. Intervention effects on HRQoL were analysed using quantile regression comparing treatment groups across time.
A total of 87 were randomised to intervention and control groups. There were generally no statistically significant differences between the groups on any HRQoL item except for pain. There was an arm (F(1, 219) = 5.0. p = 0.027) and time (F(2,221) = 4.8, p = 0.009) effect, reflecting the higher pain scores in the control group when collapsed across time points (median difference 16.7, CI 1.9 to 31.4, p = 0.027). For global HRQoL, the intervention group increased by 8.3 points between T1 and T2. The overall group median when collapsed across time was 16.7 points CI 8.2 to 25.2, p <0.001) greater in the intervention group than controls.
While the PPARCS intervention resulted in significant increases in PA, participants indicated a high HRQoL at baseline, leaving little room for improvement. Findings suggest that PA may improve global HRQoL and pain in breast and CRC survivors.
PPARCS试验研究了一种基于距离的可穿戴设备和健康指导干预措施对生活在非都市地区的乳腺癌和结直肠癌(CRC)幸存者增加身体活动(PA)的效果。本文探讨了该干预措施在12周(T2;干预结束时)和24周(T3;随访)时对健康相关生活质量(HRQoL)的影响。
将身体活动不足且已成功完成癌症治疗的参与者随机分为干预组或对照组。在基线、T2和T3时使用ActiGraph(GT9X)评估PA。使用分位数回归分析干预对HRQoL的影响,比较不同时间点的治疗组。
共有87名参与者被随机分为干预组和对照组。除疼痛外,两组在任何HRQoL项目上一般无统计学显著差异。存在组间效应(F(1, 219) = 5.0,p = 0.027)和时间效应(F(2,221) = 4.8,p = 0.009),反映出在各时间点合并后对照组的疼痛评分较高(中位数差异16.7,CI 1.9至31.4,p = 0.027)。对于总体HRQoL,干预组在T1和T2之间增加了8.3分。在各时间点合并后,干预组的总体组中位数比对照组高16.7分(CI 8.2至25.2,p <0.001)。
虽然PPARCS干预使PA显著增加,但参与者在基线时表示HRQoL较高,改善空间不大。研究结果表明,PA可能改善乳腺癌和CRC幸存者的总体HRQoL和疼痛状况。